A randomised, controlled, investigator-sponsored trial of squalamine eye drops in patients with diabetic macular oedema.
Status: Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 14 Feb 2018
Price : $35 *
At a glance
- Drugs Squalamine (Primary)
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- 14 Feb 2018 Status changed from planning to withdrawn prior to enrolment as company has discontinued further development of squalamine to preserve cash and to evaluatie strategic alternatives to maximize shareholder value, according to an Ohr Pharmaceutical media release.
- 10 Apr 2014 New trial record